Cargando…
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
Overexpression of P-glycoprotein (P-gp) is a potential cause of multidrug resistance (MDR) in tumours. We have previously reported that XR9051 (N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phenyl)-3-((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-piperazinylidene)methylbenzamide) is a p...
Autores principales: | Mistry, P, Plumb, J, Eccles, S, Watson, S, Dale, I, Ryder, H, Box, G, Charlton, P, Templeton, D, Bevan, P B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362811/ https://www.ncbi.nlm.nih.gov/pubmed/10206276 http://dx.doi.org/10.1038/sj.bjc.6690267 |
Ejemplares similares
-
Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
por: Dale, I. L., et al.
Publicado: (1998) -
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005) -
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II
por: Twelves, C J, et al.
Publicado: (1999) -
Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model
por: Takeshita, H, et al.
Publicado: (2000) -
Dosimetric evaluation of GAFCHROMIC® XR type T and XR type R films
por: Dini, Sharifeh A., et al.
Publicado: (2005)